Basic and clinical studies on BMY-28100 and its clinical evaluation in respiratory tract infections

Seuchi Aonuma, Kotaro Oizumi, Akira Watanabe, Masakichi Motomiya, Kiyoshi Konno, Kosaku Nagai

    Research output: Contribution to journalArticlepeer-review

    Abstract

    We examined the in vitro antimicrobial activity of BMY-28100, a newly developed cephem antibiotic, by the broth dilution method using the MIC-2000 System. Minimum inhibitory concentrations (MICs) of BMY-28100 against 120 clinical isolates were compared with those of cefaclor (CCL) and cefixime (CFIX). Against Staphylococcus aureus, BMY-28100 was much more active than CCL and CFIX, but against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae and Pseudomonas aeruginosa, it was as active as CCL and much less active than CFIX. Twelve patients suffering from respiratory tract infection received orally 750mg or 1000mg of BMY-28100 a day. Clinical response was excellent in 1, good in 7, fair in 1 and poor in 3 patients. Mild anemia was observed in one patient.

    Original languageEnglish
    Pages (from-to)214-221
    Number of pages8
    JournalChemotherapy
    Volume37
    DOIs
    Publication statusPublished - 1989 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Basic and clinical studies on BMY-28100 and its clinical evaluation in respiratory tract infections'. Together they form a unique fingerprint.

    Cite this